Syquant Capital’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
Syquant Capital's TPTX Position: Q3 2022 in Review
Syquant Capital sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 4,500 shares — an estimated $339K sold.
Syquant Capital first reported a position in TPTX in Q4 2020 and held it in 2 quarters. The position peaked at $609K in Q4 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- Syquant Capital reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Syquant Capital sold 4,500 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $339K.
- Syquant Capital first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
- Syquant Capital's Turning Point Therapeutics, Inc. Common Stock position peaked at $609K in Q4 2020.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on Syquant Capital's 13F filing for Q3 2022, filed 11 Oct 2022.